AA
HZNP

Apriem Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Apriem Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-2,262
Closed -$79K – 636
2015
Q2 		$79K Buy
+2,262
New +$69K 0.03% 164

Other funds holding HZNP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $16.4B AUM 99.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Apriem Advisors's HZNP Position: Q3 2015 in Review

Apriem Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2015, closing a stake of 2,262 shares — an estimated $79K sold.

Apriem Advisors first reported a position in HZNP in Q2 2015 and held it in 1 quarter. The position peaked at $79K in Q2 2015. 223 funds tracked by Wall St. Rank hold HZNP as of Q3 2015.

  • Apriem Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2015 after selling out during the quarter.
  • Apriem Advisors sold 2,262 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2015, an estimated $79K.
  • Apriem Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2015 and held it in 1 quarter.
  • Apriem Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $79K in Q2 2015.
  • 223 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2015.

Based on Apriem Advisors's 13F filing for Q3 2015, filed 13 Nov 2015.